Twenty-one years ago, we set out to prove the market wrong about a first-of-its-kind systemic photoprotective drug. The market had already decided it couldn't be done. SCENESSE® is the proof. We are now doing it again. Moving from a single successful product to a peptide platform with real formulation expertise. A clinical pipeline with regulatory backing. A balance sheet built to survive whatever the next crash looks like.
Dr Philippe Wolgen
Chief Executive Officer
CLINUVEL Pharmaceuticals Limited
FY2026 Financial Outcomes
Revenues
A$94.0m
Profit (Before tax)
A$47.7m
Cash reserves*
A$252.1m
Return on Equity
13%
*Cash reserves as stated in a non-IFRS measure
Key Achievements
- CUV105 case reports – twelve have been presented to global conferences and demonstrate re-pigmentation of patients with skin types IV-VI
- Manufacturing process of NEURACTHEL® Instant validated – working towards European regulatory filing
- Global growth in EPP patients, treatment centres and frequency of dosage
- Interactions with Health Canada leading to grant of a Notice of Compliance in July 2026 to market SCENESSE® to Canadian EPP patients
- Tenth consecutive annual profit and ninth consecutive annual dividend
- Prominent presence at American Academy of Dermatology Meeting, Denver, Colorado
THE PATH TO DIVERSIFICATION
FY 2027 Outlook
- Expansion of the VALLAURIX RD&I Centre
- Full U.S. listing being actively considered
- Commencement of CUV107 in H2 2026
- Full Results of CUV105 in H1 2027
- PhotoCosmetics launch of M-lines Preserve and Bronze in H2 2027